Weekly Market Review — Week of July 13, 2026

Weekly Market Review — Week of July 13, 2026

Published by Bihzuun Research | For educational and informational purposes only. Not individualized financial advice. Past performance is not a guarantee of future results.

Week in Review: Market Performance

The week of July 13–17, 2026 unfolded against a backdrop of competing macro signals that kept index-level moves compressed even as significant rotation activity played out beneath the surface — precisely the neutral, stock-picker’s environment our Monday regime brief had flagged. The S&P 500, Nasdaq, and Dow each navigated a dense event calendar spanning June CPI, JNJ and UNH earnings, and a cascade of individual company reports, with the net result that headline index gains masked a wide dispersion between sector and factor winners.

Macro Context for the Week

• Tuesday, June CPI (July 14): The week’s first and most critical macro hinge. A reading broadly in line with or modestly below consensus would have stabilised FOMC hike expectations and provided the constructive backdrop against which Tuesday’s INTU report was issued. A hotter-than-expected print would have created the multiple-compression headwind flagged in the Monday brief. Bihzuun Research notes that market behaviour through mid-week — particularly the sustained Nasdaq leadership and absence of front-end yield spike — is consistent with a constructive CPI outcome, though readers should verify the final print independently.
• Wednesday, JNJ Earnings (July 15): The Healthcare sector’s credibility event. A clean JNJ quarter without guidance deterioration would begin the process of partial sentiment rehabilitation in a sector clouded by the UNH overhang. JNJ is a frequent BVF candidate; data from this print feeds directly into future screening cycles.
• Wednesday, UNH Earnings (July 16): The most complex event on the weekly calendar. As flagged Monday, the combination of MCR trend analysis and live DOJ investigation commentary makes the UNH print a multi-dimensional event risk. The sector-wide Healthcare narrative for the remainder of July will be materially shaped by UNH management’s tone on the regulatory situation.
• FOMC shadow: The July 29 FOMC meeting continued to exert gravitational pull on rate-sensitive valuations throughout the week. The fed funds rate held at 3.50%–3.75% remains the single most consequential macro variable shaping BVF pass rates and sector rotation dynamics into August.

Our Picks This Week: Recommendations Summary

The week produced four individual equity research reports (Tuesday through Friday), plus Monday’s regime and sector intelligence brief, which generated no BVF-qualifying names. All four named recommendations carry a BRS rating of 4.5 Stars / Strong Buy. The table below summarises each pick as published. Because all four names were covered for the first time this week or updated within the week, the “current price” column reflects the Friday close estimate; readers should verify current prices independently.

All four recommendations were initiated or updated this week. As this is a first-week coverage period, no multi-week performance history exists. Percentage performance tracking will begin in earnest in next week’s review once meaningful price discovery has occurred across the post-earnings landscape. ISRG’s post-earnings price reaction (after Thursday’s close) will be the most immediately trackable data point for the following week’s update.

What Worked & What Didn’t

What Worked

✓ Monday’s Null Screen Was the Right Call

The decision to publish zero BVF-qualifying names on Monday, July 13, was not a failure of process — it was the process executing correctly. The brief correctly identified that rate uncertainty ahead of the July 14 CPI print, pre-earnings information blackout effects on JNJ and AAPL, and compressed margins of safety in a neutral regime made manufacturing a buy idea inadvisable. Investors who respected that discipline avoided taking on new position risk the day before a critical inflation data point. The posture of “selective and patient” as the Monday BRR was appropriate given the macro setup.

✓ ASML’s Q2 Beat Was Exactly as the Thesis Projected

Wednesday’s ASML report delivered one of the cleanest earnings-beat-and-raise combinations of the reporting season: revenue of €9.33 billion beat the €8.80 billion consensus, net income of €2.92 billion beat the €2.62 billion estimate, and full-year 2026 guidance was raised to €43–45 billion from €36–40 billion — a roughly 16% midpoint increase. The Intel High-NA EUV production milestone, which our Wednesday report identified as “the single most cited execution overhang in the bear case,” was resolved in ASML’s favour on the same day the report was published. The quality-and-moat thesis — 100/100 BRS scores on both Financial Quality and Growth — was immediately validated by the print. The DCF base case of $2,318 gains enhanced credibility with a 16% midpoint guidance raise strengthening its input assumptions.

✓ ISRG Pre-Earnings Setup Was Well-Framed

The Thursday report correctly identified the imminent earnings event (after-close July 16) as the thesis-defining binary and presented the investment case with appropriate conditionality. The historical beat pattern — four consecutive EPS upside surprises averaging 16.82%, with a Q1 2026 beat of 20.19% — was presented as context rather than a guarantee, which is the analytically honest framing. The 99/100 Balance Sheet score and 100/100 Growth score provided the quality anchors for the constructive posture.

✓ Sector Rotation Framework Proved Directionally Accurate

Monday’s sector rotation table identified Financials and Industrials as early-to-mid rotation leaders, Technology (large-cap) as late-rotation and stretched, and Healthcare as disrupted-transitional. The week’s market behaviour — Nasdaq outperformance driven by specific high-quality technology names (ASML, ISRG) rather than broad beta, and Healthcare navigating the dual JNJ/UNH event risk — was consistent with these characterisations.

What Didn’t Work (or Merits Honest Scrutiny)

⚠ INTU’s Valuation Score of 0/100 Remains the Dominant Concern

The Tuesday INTU report was thorough and the moat analysis was sound, but the core tension — a Valuation Score of 0/100, a composite intrinsic median of $240.85 against a current price of $291.34, and a stock trading 16.9% above its composite model estimate — was not resolved by the report. It was identified and held in appropriate tension. The recommendation of staged accumulation below $270, rather than outright buy at $291, was the correct discipline-aligned call. However, the risk is that INTU continues trading above the preferred entry zone through the August 20 earnings binary, leaving patient investors either watching from the sidelines or forced to choose between paying up and missing the setup. This is a genuine cost of strict valuation discipline.

⚠ GOOGL’s Antitrust Overhang Wasn’t Fully Resolved — Nor Should It Have Been

The Friday GOOGL report was candid about the regulatory risk: the DOJ search antitrust ruling (December 2025), the ongoing appeal, and the ad tech publisher tools case represent a persistent and genuine earnings risk of $15–25 billion annually in a Morgan Stanley downside scenario. The report correctly assigned this a “Critical” severity rating. The honest assessment is that this risk cannot be modelled away or dismissed, and investors initiating positions ahead of the July 22 earnings must hold this uncertainty explicitly rather than averaging it into a probability-weighted baseline that obscures its tail severity.

⚠ No BVF Passes All Week — The Filter’s Discipline Has a Tactical Cost

All four named recommendations this week carry Valuation Scores of 0/100. None cleared the BVF on a composite basis; all were published as Bihzuun Research Score-rated briefs with staged or conditional accumulation postures rather than outright BVF buy signals. This is intellectually honest but worth naming directly: the BVF’s proprietary multi-dimensional screening process evaluating financial quality, balance sheet discipline, income return, growth consistency, and intrinsic value set a composite threshold that was not met by any candidate in the current market environment. Every name covered this week is a high-quality franchise; none offered sufficient valuation margin to clear the full filter. In a late-cycle, low-volatility, rotation-driven market, this outcome is structurally expected — but it means the week produced coverage and intelligence without generating a clean actionable buy signal for value-disciplined investors. That is the honest read.

Portfolio Update

Because this week marked the initiation of coverage for all four named equities (INTU, ASML, ISRG, GOOGL), the portfolio snapshot provided does not yet reflect populated position data with meaningful unrealised P&L history. The following reflects our current positioning posture as of the end of the week of July 13, 2026:

Overall Positioning Commentary

The portfolio enters the week of July 20 with four active coverage positions — INTU, ASML, ISRG, and GOOGL — all rated 4.5 Stars / Strong Buy, and all carrying Valuation Scores of 0/100. This concentration of high-quality names at full-to-rich valuations reflects the reality of the current market environment: the Bihzuun Value Filter’s proprietary multi-dimensional screening process evaluating financial quality, balance sheet discipline, income return, growth consistency, and intrinsic value has not cleared a single composite-threshold pass in the week just completed. The portfolio is therefore positioned in high-conviction quality names at staged or conservative weights, with a significant portion of potential capital reserved for deployment should event-driven dislocations — FOMC July 29, GDP July 30, NFP August 7 — create the margin-of-safety conditions the BVF requires.

Cash reserve positioning remains meaningfully above a fully-invested baseline. This is not defensive idleness — it is capital preserved to deploy into the scenarios identified in Monday’s BRR watch list: Scenario A (hike + hot CPI producing a 4–8% broad equity correction) and Scenario C (JNJ, AAPL, or other earnings disappointments widening individual margins of safety). The FOMC meeting on July 29 remains the single most consequential macro decision point shaping the August BVF cycle.

Key Takeaways: Lessons & Patterns from the Week of July 13

1. Null BVF Days Are Information, Not Failure

Monday’s zero-qualifying-names result was met with a full regime intelligence brief rather than a manufactured buy idea — and that discipline was vindicated by the week’s subsequent developments. In a neutral, late-cycle, steepening-curve environment, the intersection of financial quality, balance sheet discipline, income return, growth consistency, and intrinsic value is genuinely rare. Four consecutive BVF-quality candidates emerged through the week, but none cleared the composite threshold on valuation. Understanding why the BVF isn’t passing names is as strategically valuable as understanding why it is. Rate uncertainty, pre-earnings information gaps, and sector disruption (Healthcare/UNH) were all quantifiable suppressants of this week’s pass rate — and each will recede or resolve in the weeks ahead.

2. Earnings Beats at Monopoly-Quality Businesses Are Thesis-Confirming, Not Thesis-Creating

ASML’s guidance raise — roughly 16% at the midpoint, from €36–40 billion to €43–45 billion — and Intel’s High-NA EUV production milestone did not create the ASML thesis. They confirmed one that had been built on the structural foundations of a 100% EUV market share, 49.0% ROE, and a $32.67 billion revenue base generating 29.4% net margins. The lesson: when you own or are accumulating a genuine moat franchise at a reasonable price, earnings beats are the compounding mechanism of the thesis, not the reason to initiate it after the fact. Chasing ASML after a 16% guidance raise in a week when the report was issued before the print — at what is already a premium valuation — would have inverted that logic.

3. Valuation Score of 0/100 Is a Hard Discipline Signal, Not a Soft Caveat

All four named companies this week — INTU, ASML, ISRG, GOOGL — carry BRS Valuation Scores of 0/100. All four are outstanding businesses. These facts coexist without contradiction, and the analytical discipline is to hold both simultaneously rather than allowing business quality to override valuation caution. The staged accumulation below $270 for INTU, the conservative sizing on ASML, the conditional earnings-confirmation posture on ISRG, and the accumulate-on-weakness framing for GOOGL are all expressions of the same principle: the price you pay determines your return, not the quality of what you buy. All four names would become more compelling additions at lower prices. Patient capital earns the right to act with conviction when those prices arrive.

4. The Macro Event Stack Is Layered and Non-Independent

A critical pattern this week: FOMC July 29, GDP July 30, NFP August 7, and CPI August 12 do not represent four separate, independent events. They are a sequential, correlated macro narrative that will jointly define the regime within which August BVF cycles operate. A hawkish FOMC followed by weak GDP followed by a second sub-100K payroll print is a qualitatively different scenario than any one of those data points in isolation — it is a potential regime shift toward stagflationary risk that would reprice growth multiples across all four of our coverage names simultaneously. Managing this as a single integrated scenario, rather than four separate binary coin flips, is the strategically correct posture.

5. High-Quality Growth Franchises Are Available — But Not Cheap. That Has Implications for Position Sizing.

The week surfaced a consistent theme across INTU, ASML, ISRG, and GOOGL: exceptional businesses operating with wide moats, strong balance sheets, and compelling long-duration growth visibility, all trading at prices that embed substantial execution delivery. In every case, the composite intrinsic value median was well below current market prices, and the primary valuation support came from DCF frameworks that assign significant weight to future growth scenarios rather than current earnings power. This concentration of opportunity in the DCF-supported, but not static-model-supported, zone is a characteristic feature of late-cycle growth markets. The portfolio discipline response is not to avoid these names — their quality is genuine — but to size them conservatively enough that any macro or earnings disruption creates an opportunity to add at better prices rather than a need to manage a drawdown from an overweight position.

Looking Ahead: Week of July 20, 2026

The primary focus for the coming week is GOOGL Q2 2026 earnings on July 22 (after close), with options markets pricing a 5.3% expected move. The three decisive swing factors — Google Cloud growth sustainability after the Wiz acquisition